August 11, 2020 Clinical Research/Diagn. Life Science Tools Product Launch

Bio-Techne Announces Release of a New SARS-CoV-1/2 Spike RBD Llamabody Recombinant Antibody That Blocks Viral Entry

MINNEAPOLIS, Aug. 11, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ:TECH) today announced the release of the SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody, which binds to the SARS-CoV-2 spike receptor binding domain (RBD) and blocks the virus from binding to its host receptor, ACE-2, inhibiting viral infection . The SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody is the... Read more

August 6, 2020 Life Science Tools M&A, Partnerships

Bio-Techne and Nanostring Announce Offering of RNAscope Reagents Validated for Use With the GeoMx Digital Spatial Profiler

Curated Menu of Off-the-Shelf RNAscope Probes Provide Molecularly-Guided Region of Interest Selection for Use with the New NGS-Enabled Cancer Transcriptome Atlas MINNEAPOLIS and SEATTLE, Aug. 6, 2020 /PRNewswire/ — Bio-Techne (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic markets and NanoString Technologies, Inc. (NASDAQ:NSTG), a leading... Read more

August 3, 2020 Clinical Research/Diagn. Life Science Tools M&A, Partnerships

Bio-Techne and Kantaro Biosciences to Launch a Quantitative Research Use Only COVID-19 Serology Test

MINNEAPOLIS and NEW YORK, Aug. 3, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced the anticipated launch of the COVID-SeroIndex, a Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO kit. Bio-Techne and Kantaro will leverage a joint commercialization and distribution team... Read more

August 3, 2020 PR/Corporate

Bio-Techne Announces Appointment of Julie L. Bushman to Its Board of Directors

MINNEAPOLIS, Aug. 3, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Julie L. Bushman to serve as an independent director on the company’s board of directors, effective as of July 31, 2020.  Following the appointment, the board of Bio-Techne will be comprised of ten directors, nine of whom are independent.  Bushman, 59, is the former... Read more

July 21, 2020 Clinical Research/Diagn. Life Science Tools Product Launch

Bio-Techne Announces Launch of Exocovid-19 Test for Detection of SARS-CoV-2 in Patient Samples

MINNEAPOLIS, July 21, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed validation testing for COVID-19 caused by the novel coronavirus (SARS-CoV-2) and now offers the ExoCovid-19 test for detection of the virus in patient samples. The ExoCovid-19 test will be performed in its CLIA-certified, CAP-accredited laboratory. Exosome Diagnostics, the... Read more

July 20, 2020 Life Science Tools Product Launch

Bio-Techne Announces Commercial Release of New Assay for Detecting ASOs, miRNAs, and siRNAs in Tissue

Expanding research tools to detect small non-coding RNAs in situ by combining molecular information with spatial context. MINNEAPOLIS, July 20, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the RNAscope™ platform with the release of the miRNAscope™ Assay. The RNAscope technology is an advanced in situ hybridization assay for the spatial visualization... Read more

June 9, 2020 Clinical Research/Diagn. M&A, Partnerships

Bio-Techne and Zero – The End of Prostate Cancer Announce Partnership to Fund Education and Awareness Campaigns to Empower Men With Prostate Cancer

MINNEAPOLIS, June 11, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has established a new partnership with ZERO – The End of Prostate Cancer, the leading national nonprofit organization in the fight against prostate cancer. ZERO advances research, improves the lives of men and families, and inspires action for patients,... Read more

June 8, 2020 Life Science Tools Product Launch

Bio-Techne Announces Release of GMP ProDots Proteins to Support Cell and Gene Therapy Manufacturing Workflows

MINNEAPOLIS, June 8, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ:TECH) today announced the release of GMP ProDots™ Proteins to support cell and gene therapy manufacturing workflows. GMP ProDots™ Proteins address a critical need to precisely dose and safely add essential proteins such as growth factors and cytokines to therapeutic cell cultures. GMP ProDots Proteins, produced under GMP-grade conditions... Read more

May 26, 2020 Clinical Research/Diagn. Life Science Tools Product Launch

Leica Biosystems and Bio-Techne Announce European Launch of the CE-IVD RNAscope in Situ Hybridization Detection Kit

MAY 26, 2020 The CE-IVD marked system will enable diagnostic pathologists with new applications MINNEAPOLIS, May 26, 2020 /PRNewswire/ — Bio-Techne (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities and Leica Biosystems, a global leader in workflow solutions and automation, are proud to announce... Read more

April 16, 2020 Life Science Tools Product Launch

Bio-Techne Introduces Replex Capabilities for Simple Western Assays on Jess

APRIL 16, 2020 MINNEAPOLIS, April 16, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced the upcoming release of RePlex™ for use on the Jess instrument, a member of the Simple Western™ instrument family. RePlex adds to Jess’s already advanced, fully automated, capillary electrophoresis-based Western blotting capabilities by allowing users to analyze the same sample twice... Read more